Julie Rubinstein - Mar 6, 2023 Form 4 Insider Report for Adaptive Biotechnologies Corp (ADPT)

Role: President
Signature: /s/ Julie Rubinstein by Stacy L Taylor, Attorney-in-Fact
Stock symbol: ADPT
Transactions as of: Mar 6, 2023
Transactions value $: -$194,265
Form type: 4
Date filed: 3/8/2023, 07:01 PM
Previous filing: Mar 8, 2022
Next filing: Mar 6, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ADPT	Common Stock	Award	$0	+133K	+58.71%	$0.00	359K	Mar 6, 2023	Direct
transaction	ADPT	Common Stock	Sale	-$194K	-22.7K	-6.31%	$8.57	337K	Mar 6, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ADPT	Stock Option (right to buy)	Award	$0	+200K		$0.00	200K	Mar 6, 2023	Common Stock	200K	$8.46	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by Issuer's election under the equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
F2	The options vest with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereunder at the end of each full month of continuous service until fully vested.

Content

This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by Issuer's election under the equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

The options vest with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereunder at the end of each full month of continuous service until fully vested.